Analysts/Institutional Investor Meet/Con. Call Updates

August 04, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Earnings Call Transcript for Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call held on July 30, 2026 at 2:30 P.M Dear Sir/ Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed transcript for the Jagsonpal Pharmaceuticals Limited Q1FY27 Earnings Conference Call held on July 30, 2026 at 2:30 P.M. for discussion of Q1 FY27 Financial Results. The same is also uploaded on Company’s website. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Encl.: A/a “Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call” July 30, 2026 MANAGEMENT: MR. MANISH GUPTA – MANAGING DIRECTOR, JAGSONPAL PHARMACEUTICALS LIMITED MR. AMRUT MEDHEKAR – CHIEF OPERATING OFFICER, JAGSONPAL PHARMACEUTICALS LIMITED MR. NIRAV VORA – CHIEF FINANCIAL OFFICER, JAGSONPAL PHARMACEUTICALS LIMITED MODERATOR: MS. SOUMYA CHHAJED – GO INDIA ADVISORS Page 1 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 Moderator: Ladies and Gentlemen, Good Day and Welcome to Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call. As a reminder, all participants' lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing “*” then “0” on your touchtone phone. Please note that this conference is being recorded. I now hand over the call to Ms. Soumya Chhajed from Go India Advisors. Thank you and over to you ma'am. Soumya Chhajed: Good day, everyone and welcome to Q1 FY27 Earnings Call of Jagsonpal Pharmaceuticals Limited. We have on call with us Mr. Manish Gupta – Managing Director, Mr. Amrut Medhekar – Chief Operating Officer and Mr. Nirav Vora – Chief Financial Officer. Please be reminded that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risk pertaining to the business. I now request the Management to take us through the same and provide some more insight on the quarter and year gone by. Post that, we will open the floor to Q&A. Thank you and over to you sir. Manish Gupta: Yes, thank you Soumya and good afternoon, everyone. Thank you for joining us. We are happy to share that we have started the first quarter on a positive note. The green shoots of growth which became visible in Q4 of last year are gaining roots and we have started the year stronger with a 9% growth in Q1. The strong performance is also reflecting in the Pharmarackdata where JPL grew by about 18.9% in the quarter as against the industry growth of 11.6% in the period. I do believe that we are now on track of getting our growth to 1.5x industry growth rate in the quarters to come. This 9% growth in sales has translated into a 21% growth in operating EBITDA as well as a 22% growth in net profits for the company. A key milestone during the quarter was the acquisition of controlling stake in Aequitas Healthcare at an enterprise value of about Rs.25 crores. Page 2 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 With FY26 revenue of Rs.53 crores, Aequitas provides JPL an immediate and meaningful entry into the hospital segment, thereby creating new opportunities through hospital formulary access, cross- selling and operating synergies. I am confident that this acquisition will start contributing meaningfully to JPL's business from second year onwards. Alongside investing for growth, continuing our tradition for rewarding shareholders, we completed a Rs.40 crores share buyback which has strong positive impact on our already healthy return on capital employed by another 340 bps. The buyback, which was subscribed 3.67x was made at a premium of about 40% to the then prevalent market price. Importantly, we have recouped almost 50% of this payout within this quarter, reflecting the strength of our business model as also discipline of execution. Over the last four years, we have focused on building a business that consistently delivers profitable growth, strong cash generation and disciplined capital allocation. Between FY22 and FY26, our EBITDA and PAT has grown 2.5x, compounding at almost 25% annually, while our free cash flows have increased 8x. This transformation has enormously strengthened our balance sheet, which coupled with our integration skills, has positioned us well in pursuing strategic inorganic opportunities. The quarter gone by also saw a change in the Board of Directors. We acknowledge the valuable contribution of Ms. Pallavi Dinodia Gupta over the last four years, who stepped down citing personal commitments. We are delighted to welcome Mr. Anil Kumar Matai, who joins the Board as an Independent Director. Mr. Matai brings with him more than three decades of distinguished leadership experience across pharmaceutical and healthcare sectors. With his rich experience and deep understanding of the industry, Mr. Matai brings immense value as we continue to scale our business and pursue growth opportunities. Looking ahead, our priorities remain unchanged, accelerating organic growth, successful integration of Aequitas and evaluating value-accretive inorganic opportunities, all while maintaining disciplined capital allocation. With that, I now hand over the call to our Chief Operating Officer – Amrut, to Discuss the Operational Performance. Page 3 of 17 Jagsonpal Pharmaceuticals Limited July 30, 2026 Amrut Medhekar: Good afternoon, everyone and thank you, Manish and thank you, all for joining the call. Let us talk about how we are moving Jagsonpal from good to great in the Indian pharma market. This quarter was not just about steady execution, but we believe that some of the steps taken in the right direction have started showing some positive outcomes. We have laid the groundwork for a new phase of value creation built on four clear pillars -- One, which is accelerating organic growth. Second, brand building. Third, productivity increase. And fourth, inorganic value-accretive opportunities. Here is the plan and what we have started delivering. In terms of accelerated organic growth, our branded prescription business is the engine of Jagsonpal and this quarter we tuned that engine. We are deliberately shifting the portfolio away from high volume and low margin acute therapies towards higher value, stickier semi-chronic and specialty treatments. The increasing focus on semi-chronic and specialty therapies has significantly enhanced our quality and productivity of our new launches, with average monthly sales run rate almost doubling for these new brands. This is a structural change and it would not happen overnight, but we are confident that we will see more meaningful results in the coming future. This strategy is not just about changing geography and scale, it is about deepening our clinical relevance. By launching some complex generics and niche formulations, we are taking share in the premium tier. Our semi-urban push, backed by highly trained field force, is already improving month-on-month market share as well as rankings. We are growing faster than the industry and the revenue that we are adding is of superior quality. Second pillar is our brand building efforts. In India, products meet the needs and brands earn loyalty. We have rebalanced our marketing investments to move Jagsonpal from a product-centric to brand- centricity. We are shifting our traditional volume-led promotional practices to a more focused scien [Showing first 8,000 characters — download PDF for full document]